Nuvalent fetches $50m Series A
Nuvalent Inc, a creator of precisely targeted therapies for clinically proven kinase targets in cancer, has secured $50 million in Series A financing.
Nuvalent Inc, a creator of precisely targeted therapies for clinically proven kinase targets in cancer, has secured $50 million in Series A financing.
Copyright PEI Media
Not for publication, email or dissemination